-
Mashup Score: 18High TMB in NSCLC and Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade - 2 year(s) ago
This cohort study examines the association between increasing tumor mutation burden (TMB) levels and immunotherapy efficacy across clinically relevant programmed death ligand–1 (PD-L1) levels in patients with non–small cell lung cancer (NSCLC).
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 6High TMB in NSCLC and Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade - 2 year(s) ago
This cohort study examines the association between increasing tumor mutation burden (TMB) levels and immunotherapy efficacy across clinically relevant programmed death ligand–1 (PD-L1) levels in patients with non–small cell lung cancer (NSCLC).
Source: jamanetwork.comCategories: Latest Headlines, Oncologists1Tweet-
RT @ADesaiMD: "High #TMB in #NSCLC #LCSM and ⬆️Immune Infiltration and Improved Outcomes of #PDL1 Blockade" https://t.co/kMbSfOYPuy @JAMAO…
-
-
Mashup Score: 5High TMB in NSCLC and Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade - 2 year(s) ago
This cohort study examines the association between increasing tumor mutation burden (TMB) levels and immunotherapy efficacy across clinically relevant programmed death ligand–1 (PD-L1) levels in patients with non–small cell lung cancer (NSCLC).
Source: jamanetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @ADesaiMD: "High #TMB in #NSCLC #LCSM and ⬆️Immune Infiltration and Improved Outcomes of #PDL1 Blockade" https://t.co/kMbSfOYPuy @JAMAO…
-
-
Mashup Score: 3
PURPOSE Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier: NCT03081689). The 3-year overall survival (OS) and circulating tumor DNA (ctDNA) analysis have not been reported. METHODS This was an open-label, multicenter, single-arm, phase II trial in which patients with stage IIIA…
Source: Journal of Clinical OncologyCategories: Latest Headlines, Oncologists2Tweet-
Impressive 81.9% overall survival rate at 36mo with #neoadjuvant chemo+#Immunotherapy and #adjuvant #Immunotherapy for non-small-cell #lungcancer in the Nadim study and #ctDna superior biomarker than #pdl1 #tmb #recist and #pCR https://t.co/QG7TvoyV9d @OncoViews @OncoAlert https://t.co/z5ubt7y10V
-
-
Mashup Score: 0Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a meta-analysis | Immunotherapy - 2 year(s) ago
Aims: We performed a meta-analysis to investigate the predictive value of PD-L1 in metastatic renal cell carcinoma (mRCC) patients receiving immune-based combinations versus sunitinib monotherapy. Materials & Methods: Outcomes of interest included OS and PFS; HRs and their 95% CIs were extracted. Results: The pooled HR for OS was 0.71 (95% CI: 0.61–0.84) and 0.75 (95% CI: 0.68–0.82) in…
Source: ImmunotherapyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Read the ahead of print meta-analysis of the predicitive power of #PDL1 status in #mRCC treated with monotherapy and immune combinations 📚 https://t.co/SxF6DvHm1G https://t.co/TK49Vb3nST
-
-
Mashup Score: 1Tumor-intrinsic PD-L1 promotes DNA repair in distinct cancers and suppresses PARP inhibitor-induced synthetic lethality - 2 year(s) ago
Abstract. BRCA1-mediated homologous recombination is an important DNA repair mechanism that is the target of FDA-approved PARP inhibitors, yet details of BRCA1-mediated functions remain to be fully elucidated. Similarly, immune checkpoint molecules are targets of FDA-approved cancer immunotherapies, but the biological and mechanistic consequences of their application are incompletely understood….
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Immune #CheckpointBlockade can directly affect cancer cell functions. Kornepati et al find that #PDL1 promotes DNA double-strand break repair by homologous recombination. https://t.co/8Guf7dx09E @uthealthaustin #AACR22 https://t.co/Zv7LXz4ogl
-
-
Mashup Score: 0
The therapeutic management of advanced non–small cell lung cancer (NSCLC) has profoundly improved in recent years, and the treatment algorithms are not only limited to conventional cytotoxic chemotherapies, but also molecular-targeted therapies and immunotherapy [1,2]. Approximately two-thirds of patients with NSCLC harbor actionable oncogenic driver mutations, including epidermal growth factor…
Source: Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Report @LungCaJournal that high PDL1 expression in #ALK NSCLC associated with worse outcomes. #PDL1 high (23% of pts) had shorter PFS and shorter OS. Surrogate for specific variants or co-mutations? This does not equate to immunotherapy efficacy though! https://t.co/mlHbOmSChK
-
-
Mashup Score: 3
Nature Reviews Endocrinology – PDL1 reduces adipose inflammation in obesity
Source: NatureCategories: Endocrinology, Latest HeadlinesTweet-
AOP #ResearchHighlight - a new study looks at the role of #PDL1 in reducing #adipose tissue #inflammation and limiting diet-induced #obesity (£) https://t.co/BaQZN0Su7y https://t.co/tIi6mycj5t
-
-
Mashup Score: 7
Cancer cell-intrinsic PDL1 signals present novel drug discovery targets and also have potential as treatment response biomarkers. This Perspective discusses our understanding of cancer cell-intrinsic PDL1 signals, mechanisms for signal controls and immunopathological consequences including resistance to cytotoxic agents, targeted small molecules and immunotherapies.
Source: NatureCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the March issue of @NatureRevCancer | #PDL1 signals in #cancer cells by AVR Kornepati, RK Vadlamudi & TJ Curiel https://t.co/KKhYovCQgF @natrescancer #ImmuneCheckpoint #immunotherapies #therapyresistance https://t.co/ksH6wCXpKj
-
-
Mashup Score: 0Volume 22 Issue 3, March 2022 - 2 year(s) ago
Volume 22 Issue 3, March 2022
Source: www.nature.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Our March issue, out NOW! With articles on pancreatic #cancer evolution, tobacco #carcinogens, shared mechanisms of #metastasis & #therapyresistance & #PDL1 signals! Plus a Comment on racial disparities in acral #melanoma research. 💌 https://t.co/ao93JUFzOy @natrescancer https://t.co/nS6ZY7eOzo
-
RT @ADesaiMD: "High #TMB in #NSCLC #LCSM and ⬆️Immune Infiltration and Improved Outcomes of #PDL1 Blockade" https://t.co/kMbSfOYPuy @JAMAO…